5 mg cápsulas duras.

DRUG2 trials

Sponsors

Fundacion Epic

Conditions

Acute coronary syndromeDegree of control coronary risk factors and platelet aggregation

Phase 3

CROSS-OVER ANALYSIS OF THE CONTROL OF RISK FACTORS AND ANTIAGGREGATION WITH POLIPILL (POLICROSS TRIAL)

Not yet recruitingCTIS2024-518705-18-00

Fundacion EpicDegree of control coronary risk factors and platelet aggregation

Target: 88Updated: 2024-11-04

Phase 4

Combined impact of cardiovascular polypill treatment and a specific nurse education program on adherence to therapy in patients with ACS: a randomized study

Not yet recruitingCTIS2025-524751-32-00

Fundacion EpicAcute coronary syndrome

Target: 216Updated: 2026-03-30